Disease · MONDO_0005025

endocarditis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endocarditis. Diseases, record MONDO_0005025. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005025

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endocarditis; Open Targets
Open Targets ID: MONDO_0005025; Open Targets
Other names: Endocarditides, Endocarditides, Infective, Endocarditis (disorder), Endocarditis NOS, Endocarditis, Infective, Infective Endocarditides, Infective Endocarditis, acute Endocarditis, acute endocarditis (disorder), acute endocarditis NOS (disorder), acute endocarditis, unspecified, endocarditis (disease), endocardium inflammation, inflammation of endocardium, non-infective endocarditis; Open Targets
Disease Ontology: DOID:10314; Disease Ontology
MeSH: D004696; MeSH
NCI Thesaurus: C34582; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 13 drugs, from DailyMed and TTD; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CEFAZOLIN SODIUM	CHEMBL1200523	Small molecule	Approval	DailyMed	30	0	0	Drugs and targets
AMPICILLIN SODIUM	CHEMBL1200758	Small molecule	Approval	DailyMed	25	0	0	Drugs and targets
CILASTATIN SODIUM	CHEMBL1201057	Small molecule	Approval	DailyMed	7	0	0	Drugs and targets
IMIPENEM	CHEMBL43708	Small molecule	Approval	DailyMed	7	0	0	Drugs and targets
DAPTOMYCIN	CHEMBL387675	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
VANCOMYCIN HYDROCHLORIDE	CHEMBL1200628	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
FLUCYTOSINE	CHEMBL1463	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DALBAVANCIN	CHEMBL3301669	Protein	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
EXEBACASE	CHEMBL4297925	Enzyme	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
DPEP1	Dipeptidase 1	1	Renal dipeptidase inhibitor	Approval	https://conductscience.org/library/genes/1800

Source Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03163446	Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia	Phase 2	121	2021-10-08	Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis	EXEBACASE	Its record names the disease	ClinicalTrials.gov
NCT02853292	Incidence, Risk Factors and Impact on Renal Function of the Appearance of Crystalluria Under High-dose Intravenous Amoxicillin		153		Amoxicillin Crystalluria	AMOXICILLIN	Its record names the disease	ClinicalTrials.gov
NCT04959799	Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)		98		Diabetes, Infection	DALBAVANCIN	Its record names the disease	ClinicalTrials.gov
NCT06426212	Use of Teicoplanin on a Three-weekly Administration in the Infectious Diseases Unit		40		Comparison of Teicoplanin Used Three Times a Week in DSIs vs NDISs	TEICOPLANIN	Its record names the disease	ClinicalTrials.gov
NCT04847921	Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition	Phase 2/3	11		Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders, Intravenous Substance Abuse	DALBAVANCIN	Its record names the disease	ClinicalTrials.gov
NCT04691440	Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis	Phase 2	10		Infectious Endocarditis	OXYGEN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CF-301 vs Placebo: deaths from any cause	17 of 73	9 of 48	121	NCT03163446	Trial comparisons
CF-301 vs Placebo: serious adverse events	45 of 72	28 of 47	119	NCT03163446	Trial comparisons
cBSI/R-IE - CF-301 vs cBSI/R-IE - Placebo: Clinical Responders at Day 14 in Patients With cBSI/R-IE	36 of 47	22 of 39	86	NCT03163446	Trial comparisons
MRSA - CF-301 vs MRSA - Placebo: All-cause Mortality at Day 30 in MRSA Subgroup	1 of 27	4 of 16	43	NCT03163446	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38249543	DERIVED	1	PubMed
38211660	DERIVED	1	PubMed
35295665	DERIVED	1	PubMed
32271718	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005025

GET https://conductscience.org/api/diseases/v1/MONDO_0005025/drugs

API reference For AI assistants